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Abstract: The octahedral titanium(IV) complexes trans,mer-[Ti{R3N(CH2C6H2-2-O-4-R2-6-R1)2}2] 
(R1 = Me, OMe, Cl; R2 = Me, OMe, F, Cl; R3 = Me, Et; not all combinations) are synthesised in 
two steps from simple phenols in 36-53% overall yield. The highly crystalline (4 X-ray 
structures) complexes are active against MCF-7 (breast) and HCT-116 (colon) cancer cell lines 
showing widely varying GI50 values in the range 1-100 µM depending on R1-R3. Highest 
activities are realised when R1 = OMe and R2, R3 = Me (GI50 ~1 µM for MCF-7 and 2-3 µM for 
HCT-116). These are respectively 8 and 3 times greater than the activities of cisplatin in the 
same cell lines. These titanium complexes show some significant selectivity for cancer cell 
lines; up to 7 higher in MCF-7 compared to non-cancer (MRC-5) fibroblast cells. Details of 
cellular mode of action indicators (cell cycle perturbation, Annexin V, -H2AX, and caspase 
studies) that point to an apoptosis mode for the most active compound (R1 = OMe and R2, R3 
= Me) are also reported.  
 
Mohammed Abid, Ryan Nouch, Tracey Bradshaw, William Lewis, Simon Woodward – Full paper for EJIC 
 
2 
 
Introduction 
 
In 1969, cisplatin [cis-diamminedichloroplatinum(II)] first emerged as a cancer therapy, 
subsequently becoming one of the most popular antineoplastic (cytotoxic) agents employed 
against human ovarian, testicular, head, neck and bladder carcinomas. Although cisplatin 
possesses potential against most carcinomas, its toxic side-effects (myelotoxicity and 
nephrotoxicity) and problems with resistance soon became apparent.[1] Because of such 
issues, alternative metal complexes have also been explored for anti-cancer activity.[2] These 
related metal complexes can show mechanisms of action other than the DNA binding seen for 
cisplatin depending on their metal acidity/oxidation state and their supporting ligands.[3] In 
particular, titanium(IV) complexes have recently appeared showing activities higher or 
comparable to cisplatin and its Pt-based derivatives and these are thought to be promising 
anticancer drug candidates.[4] Unfortunately, progress towards potential clinical candidates 
has been hindered by a lack of understanding of the mechanism(s) of action of titanium 
agents.[5] Initial investigations in this area focused on titanocene dichloride Cp2TiCl2 (Cp = 
η-C5H5) and this candidate reached clinical trial (although its low efficacy did not allow it to 
progress beyond phase II). One of the problems in deriving the cellular mode of action of 
Cp2TiCl2, and related titanium(IV) complexes, is that while partial ligand hydrolysis is 
apparently vital in attaining the biological activity such reactions rapidly cascade providing 
complex mixtures of species. Thus, correlation of the observed cellular outcomes to a 
particular titanium species becomes difficult. With the aim of slowing down and controlling 
such hydrolysis events Tshuva has introduced polydentate phenolato ligands of type LA and 
LB.[6,7] We became intrigued as to why the related ligand cores LC, after coordination to 
titanium(IV), had not been trialled in anti-cancer studies (even though examples of such 
complexes have been known in the fields of coordination chemistry and catalysis since 
1970s).[8] We were particularly interested to see if use of ligand of type LC could lead to highly 
active titanium(IV) complexes suitable for subsequent mechanistic investigations. 
 
 
 
 
Scheme 1. Previously screened (LA, LB) and an untried class LC phenolato-amine ligand cores 
for anti-cancer trials of titanium(IV) complexes. 
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Results and Discussion 
 
Ligand and complex formation and stability 
While over 5000 examples of entities containing the sub structure core of LC (shown in bold) 
are known,[8] it is desirable for biological studies (e.g. for oxidative stability) to block sites ortho 
and para to the phenol (OH) function and to restrict R to a simple methyl unit. Only 35 
examples of such structures (2, Scheme 2) are known, where R1 and R2 are restricted to Br, Cl, 
Me, tBu and adamantyl.[8] Importantly, no examples of 2 have been reported containing 
electron-releasing OMe units, which we postulated would be the most biologically active when 
R3 = Me. We thus prepared a small library of 4,6-substituted versions of LC 2a-f (Scheme 2) 
using simple Mannich chemistry. Five moderate electron-rich ligands 2a-e containing methyl 
(σp = -0.17) and methoxy (σp = -0.27) units were prepared of which only 2a was previously 
known.[9] Non-commercial phenols (1d-e) are accessed by simple Bayer-Villiger oxidations of 
the parent aldehydes (see Supporting Information). Crude yields for 2a-e were in the range 50 
to 80+% and analytically pure materials were attained by layering pentane onto their ether 
solutions. Attempts to prepare 4,6-substituted LC from nitrogen containing 1h were 
unsuccessful (Supporting Information). For comparison electron deficient 2f (F, σp = +0.06) and 
2g (Cl, σp = +0.23) were also targeted. While 2f is prepared in moderate yield 2g could not be 
isolated pure in our hands, although it is described in the literature.[10] However, compound 
2g is clearly present in the crude mixture and this could be used for subsequent complexation 
studies (see later).  
 
 
 
Scheme 2. 4,6-substituted ligand Lc library prepared in this study. 
 
Reaction of ligands 2 at a 2:1 stoichiometry with Ti(OiPr)4 in toluene at ambient temperature 
leads to intense red coloured solutions from which complexes 3 can be isolated in good yield 
as rhomboidal crystals or orange powders upon removal of the toluene and recrystallisation 
from optimal solvents (see Supporting Information) (Scheme 3).  
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Scheme 3. Titanium complexes 3 library prepared in this study and comparison to the more 
commonly targeted motifs (A). 
Ligands of type 2 (LC) complex readily to a wide variety of transition metals including: Zr,[11] 
V,[12] Mo,[13] Mn,[14] Fe,[15] and Cu[16] However, for titanium only the preparation of 3a is 
known[17] together with three Ti(substituted-LC)2 complexes using ligands related to 2 with R1, 
R2 = Me (or its 3-isomer), tBu and R3 = Et, nPr, CH2CH2NMe2.[18] Other than that, the nearest 
related titanium complexes we could identify (ca. 180 examples[8]) were those showing the 
motifs (A) (Scheme 3), which have been prepared mostly for studies of alkene polymerisation 
catalysis.[8] Complexes 3 are chiral (but racemic) and this causes observation of characteristic 
diastereotopic aryl C-H (four 4J coupled doublets in the range H 6.61-6.44) and NCH2 (at H 
4.85-3.30 showing 2J ~12.8 Hz or second order behaviour) signals. Conveniently, complexes 3 
are all highly crystalline so that they can be easily brought to analytical purity for both 
biological and mechanistic studies (see Supporting Information for individual compounds). All 
of the compounds 3 are stable in dmso-d6 solution (10 mM) for at least 5 days at ambient 
conditions. Addition of excess D2O, simulating the serial dilutions carried out in the biological 
assessments (see later), indicated that species 3 form colloidal suspensions and that hydrolysis 
to afford ligands 2 as the major solution species is a slow process (>1 day, see Supporting 
Information). 
 
Crystallographic studies 
The molecular structure of complex 3b was determined by X-ray studies and is shown in 
(Figure 1). The same trans,mer geometry is also seen in related crystallographic studies of 3d, 
3e, 3f (see Supporting Information) and for the literature structure of 3a.[17] The ligands in 
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these series 3 contain a common CH2NMeCH2 linker so that electronic effects on bonding to 
TiO4N2 core induced by the aryl substituents can be examined. Comparing the bond distance 
and angle data for these five complexes (Table 1) reveals a very similar range of geometries. 
No significant structural correlation of the pro-drug structures of 3 to their cytotoxic activity 
(see later) was observed, implying that the observed structure-activity-relationship is due only 
to ligand electronic effects on the electron density in in vitro formed titanium species. At best 
for precursors 3 a slight distortion of N-Ti-N angles correlated with the anti-cancer activity. 
However, the latter may be due to crystal packing rather than substituent effects.  Complexes 
3d-f were found to crystallise as solvates, but these are readily lost in the absence of 
supporting solvent and all subsequent biological studies were carried out on samples of 3 
assayed as solvent free (NMR) and analytically pure (CHN).   
 
 
 
Figure 1. Molecular structure of titanium complex 3b. 
 
Table 1. Selected comparison of bond distance and angle data for titanium complexes 3a-3b 
and 3d-f for their TiO4N2 cores.[a] 
Complex 3a[b] 3b[c] 3d[c] 3e 3f 
R1 (ortho) Me MeO Me OMe Me 
R2 (para) Me Me OMe OMe F 
Bond lengths (Å) 
Ti(1)-O(1) 1.892 1.909 1.881 1.921 1.880 
Ti(1)-O(2) 1.882 1.859 1.889 1.874 1.876 
Ti(1)-O(3) 1.892 1.873 1.894 1.867 1.880 
Ti(1)-O(4) 1.882 1.900 1.878 1.887 1.876 
Ti(1)-Oave 1.887 1.885 1.885 1.887 1.878 
Ti(1)-N(1) 2.264 2.244 2.244 2.272 2.247 
Ti(1)-N(2) 2.264 2.267 2.265 2.251 2.247 
Ti(1)-Nave 2.264 2.255 2.256 2.262 2.247 
Bond angles (o) 
O(1)-Ti(1)-O(2) 168.6 167.5 167.1 165.2 167.9 
O(3)-Ti(1)-O(4) 168.6 167.6 167.9 166.4 167.9 
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N(1)-Ti(1)-N(2) 179.7 174.7 173.8 173.6 179.8 
[a] The TiO4N2 donor set is numbered in all cases as for 3b in Figure 1 (see also Supporting 
Information). [b] Based on the published SEFZIN structure.[17] [c] Average of two independent 
molecules within unit cell. 
 
 
Growth inhibitory activity of 3b-e against MCF-7 and HCT-116 
In vitro antitumor activity of all compounds (3) was assessed using the MTT assay against two 
human-derived cancer cell lines: MCF-7 (breast) and HCT-116 (colon), with cisplatin as a 
positive control for all tests, using standard protocols (see Supporting Information). 
Compound 3a has been previously reported in the literature,[17] but its anti-cancer properties 
were not determined. Trials of 3a revealed unremarkable activity (GI50 values 35-40 μM) 
against both these cell lines. Exchange of a single methyl for methoxy group in complex 3b 
resulted in >10-fold increase in anti-cancer activity. The growth inhibitory activities of 3a and 
3b are compared in Figure 2. The GI50 values of the electronically diverse complexes 3b-f were 
similarly screened by MTT assay. Complex 3b was confirmed as the most active with GI50 values 
of ~1 μM for MCF-7 and ~3.4 μM for HCT-116 (Table 2). Other compounds in the series showed 
moderate to good activity anti-cancer performance (Figure 3 and Table 2). Typically, no 
structural modifications were made to the compounds at the nitrogen donor (e.g. R3), as 
preliminary studies changing the methyl group within 3b to the ethyl derivative 3c negatively 
affected the compound class, reducing potency. The activity of 3c is similar to cisplatin, whose 
control GI50 values in our studies were 6.6 μM for MCF-7 and 9.2 μM for HCT-116 (Figure 3A-
B). We suspect 3c of being less soluble in aqueous media leading to reduced activity. Our 
results show that Ti(IV) complexes 3b-f are among the most active reported in the literature[4-
7] and that this activity is strongly dependent on the ligand structure. While 3b is the most 
potent compound, 3d showed good activity with GI50 values of 2 μM and 3 µM against MCF-7 
and HCT-116 cell lines respectively (Figure 3A-B and Table 2). Complex 3e showed lower 
potency than 3b and 3d against the same cell lines (GI50 values ~8.5 µM against both MCF-7 
and HCT-116 cells; Figure 3A-B and Table 2). Complex 3f revealed reduced activity with GI50 
values of 11.7 μM for MCF-7 and 22 μM for HCT-116 (Figure 3A-B and Table 2).  
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Figure 2.  Representative MTT graphs displaying the dose-dependent growth inhibitory 
properties of 3a-b against MCF-7 (A) and HCT-116 (B) cell lines. Cells were seeded in 96-well 
plates at a density of 3 x 103 cells/well. After allowing 24 h to adhere, cells were treated with 
the specified compound and incubated for 72 h. Data points depict mean ±S.D. n = 8; MTT 
assays were repeated >3 times. LineT0 is a control run: using just media and cancer cell line. 
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Figure 3. Representative MTT graphs displaying the dose-dependent growth inhibitory 
properties of 3b-f against MCF-7 (A) and HCT-116 (B) cell lines. Cells were seeded in 96-well 
plates at a density of 3 x 103 cells/well. After allowing 24 h to adhere, cells were treated with 
the specified compound and incubated for 72 h. Data points depict mean ±S.D. n = 8; MTT 
assays were repeated >3 times.  LineT0 is a control run: using just media and cancer cell line. 
Tetrachloro analogue 3g showed the lowest activity amongst the new derivatives of 3 
screened and was comparable to complex 3a. The 3g GI50 values were: 51.5 μM for MCF-7 and 
64.8 μM for HCT-116 (Figure S4, see Support Information). The selectivity of 3b to cancerous 
cells was evaluated by measuring its growth inhibitory activity in non-cancerous MRC-5 human 
lung fibroblast (Figure S5-A, see Support Information). Complex 3b showed reduced activity 
(cytotoxicity) toward these cells, implying a degree of cancer cell selectivity.[19]  The GI50 value 
of 3b in MRC-5 cells was higher at 7.3 μM (Table 2), indicating a ~7-fold selectivity when 
compared to activity against MCF-7 breast cancer cells. The activities of all Ti(IV) complexes 3 
were similarly assessed against MRC-5 and consistently, reduced activities were observed 
against these non-tumourigenic fibroblasts;  the GI50 values for 3e, 3f and 3g were ~16 μM , 
34 μM and >100 μM respectively. This was in complete contrast to cisplatin controls, which 
were equi-active across all three cell lines (cancerous MCF-7 and HCT-116 and benign MRC-5 
fibroblasts). Thus, the novel Ti(IV) complexes 3 demonstrate significant cancer cell selectivity 
(Table 2 and Figure S5-B in Supporting Information).    
The in vitro growth inhibitory activity of complexes 3a-g are summarised in Table 2. An 
interesting correlation is seen between the electronic properties of the phenolic substituents 
vs. the cellular cytotoxic activity. Moderate donation (R1, R2 = Me, MeO) into the phenolate 
results in increased activity, but if this is either further increased (3e) or decreased (3a, 3f, 3g) 
the biological activity falls. Bulky substitution of R3 (3b vs. 3c) also has a negative effect on 
biological performance.  
 
Table 2. Activity of complexes 3 (GI50 values in µM by MTT assay) against MCF-7 and HCT-116 
cancer cell lines and normal MRC-5 fibroblast cells. Data were generated from ≥3 independent 
trials; n = 8 per experimental condition per trial.  
3 R1 R2 R3 σp(R1)[a] σp(R2)[a] GI50 (MCF-7)  
(µM)[b] 
GI50 (HCT-
116) (µM)[b] 
GI50 (MRC-5)  
(µM)[b] 
3a Me Me Me -0.17 -0.17 36.3±0.1 38.6±0.1 >50 
3b MeO Me Me -0.27 -0.17 1.0±0.04 3.4±0.07 7.33±0.04 
3c MeO Me Et -0.27 -0.17 6.6±0.07 9.2±0.09 15.23±0.01 
3d Me MeO Me -0.17 -0.27 2.2±0.06 3.0±0.05 8.38±0.04 
3e MeO MeO Me -0.27 -0.27 8.4±0.1 8.6±0.15 16.0±0.1 
3f Me F Me -0.17 +0.06 11.7±0.05 22±0.031 34±0.03 
3g Cl Cl Me +0.23 +0.23 51.5±0.1 64.8±0.07 >100 
Cis-Pt[c] - - - - - 7.8±0.04 8.4±0.06 7.6±0.09 
[a] Hammett parameter value for para substituent.[20] [b] As determined by MTT assay (3 
duplicates). [c] Cisplatin. 
 
 
Mohammed Abid, Ryan Nouch, Tracey Bradshaw, William Lewis, Simon Woodward – Full paper for EJIC 
 
9 
 
Effect of 3b and 3d-f on MCF-7 and HCT-116 colony formation 
Having established that Ti(IV) analogues 3 cause selective growth inhibitory activity in two 
cancer cell lines, we sought to evaluate whether these cancer cells could survive a brief 
challenge of 24 h exposure to 1 µM or 5 µM of representative Ti complexes 3 and retain their 
proliferative capacity. To this end, clonogenic assays were set up. Clonogenic assays are a 
recognised technique for determining the cytotoxic potential of a test agent and results are 
typically represented as a survival fraction (%) vs control cell colony populations of non-treated 
cells. Both 3b and 3d significantly inhibited colony formation after 24 h treatment of cells at 
concentrations of 1 and 5 µM (Figure 4A-B). Complexes 3b and 3d inhibited MCF-7 colony 
formation cell at 1 and 5 µM by 40-45% and 100% respectively. Despite the fact that MCF-7 
and HCT-116 showed variable sensitivities to 3b and 3d (GI50 1.0 μM and 3.4 μM respectively), 
similar inhibition of HCT-116 colony formation was observed, 51% and 100% by 1 and 5 µM 
values respectively (Figure 4A-B). Complexes 3e and 3f also inhibited the colony formation in 
MCF-7 cells by 25% and 29% (1µM), and 57% and 48% (5 µM) respectively. The same agents 
inhibited HCT-116 colony formation by 16% and 22% (1 µM 3e and 3f) and 49% and 28% (5 
µM 3e and 3f; Figure 6A-B). Complete (100%) inhibition of colony formation was observed in 
HCT116 cells and MCF-7 exposed to 5 µM 3b and 3d, reflecting potency and cytotoxicity of 
these complexes (Figure S6 C and D, see Support Information). These data indicate that the 
cancer cells have lost their ability to form progeny colonies or have been killed (Figure S6-C, 
see Support Information).[21] Representative colonies are shown in (Figure S6 C-D, see Support 
Information). In contrast, at the concentrations adopted, 3e and 3f demonstrated reduced 
potency, therefore exposure of MCF-7 or HCT-116 cells to 1 µM or 5 µM 3e and 3f failed to 
inhibit colony formation by >50%.[22]   
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Figure 4. Effect 3b, 3d, 3e, and 3f on A) MCF-7, B) HCT-116 colony formation. A + B Mean 
survival fraction of % control represented of mean ±SEM of 5 independent trials (n = 2 per 
trial). Complexes 3b and 3d exhibited significant reduction in colony formation while 3e and 
3f showed modest activity by comparison (p < 0.0001, n = 2). 
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Cell cycle analysis   
Based on MTT and clonogenic assays, the complexes 3 compromise cancer cell viability and 
growth. Led by these observations, we examined the effect of 3b, 3f (as efficient and modest 
agents, i.e. GI50 values of  ca. 7 and 34 µM against the HCT-116 cell line respectively), and 
cisplatin (as a positive control) on cell cycle perturbation by flow cytometry. An HCT-116 
control cell cycle distribution profile demonstrated: 53.4 %, 24.9 % and 15.3 % events for the 
G1, S, G2/M phases[5] respectively. Negligible events can be detected in the preG1 
compartment reflecting a healthy HCT-116 population (Figure S7, see Supporting Information). 
In contrast, following 72 h exposure of these cells to 10 µM (~1.5 x GI50) cisplatin, a substantial 
pre-G1 population is evident (25.5 % events) indicative of cells undergoing apoptosis. It is 
known that cisplatin causes DNA inter- and intra-strand crosslinks,[23] blocking DNA replication; 
alerted DNA repair mechanisms fail to repair cisplatin-induced DNA damage (initially) initiating 
apoptosis. As DNA replication is blocked and repair is attempted, the cell cycle is halted during 
S and G2 phases. After 72 h of continued treatment, DNA repair failure triggers programmed 
cell death. No preG1 peak is evident in HCT-116 cells exposed to 10 µM (~3 x GI50) 3b; this 
Ti(IV) analogue caused a profound accumulation of events in the G2/M phases, indicating a 
different/delayed mechanism of action. If the arrested cell cycle occurs as a result of DNA 
damage, its onset may be later than that caused by cisplatin.[24] In contrast, complex 3f (at 10 
µM; <0.5 x GI50) caused negligible apparent cell cycle perturbation. MCF-7 cells exposed to 
cisplatin, 3b or 3f demonstrated modest increase in late S/G2/M events (Supplementary Figure 
S8). 
 
Induction of apoptosis in cancer cells 
Annexin-V/PI apoptosis assays[5] were performed to explore the apoptosis-inducing properties 
of 3b and 3f; cisplatin being used as a positive control. MCF-7 and HCT-116 cells were exposed 
to both complexes (5 µM and 10 µM; 72 h). Apoptotic populations were confirmed by dual 
annexin V-FITC/PI staining (Figure 5). The majority (65%) of cells exposed to 10 µM cisplatin 
(72 h) were undergoing apoptosis. Both 3b and 3f revealed profound apoptotic MCF-7 and 
HCT-116 populations at the concentrations tested. However, while early and late apoptosis 
were evident in HCT-116 cells treated with 3b, exposure to 3f for 72 h revealed a larger 
proportion of cells undergoing early apoptosis – indicating later onset of programmed cell 
death (Figure 5, and Figures S9, S10 Supporting Information).   
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Figure 5. Apoptotic effects of 3b, 3f , and cisplatin on A) MCF-7 and B) HCT-116 cells at 10 µM. 
Cells were treated with 10 µM for 72 h. Annexin-V/PI apoptosis assay was adopted to 
determine the percentage of apoptotic cells.  
 
Induction of DNA damage 
To determine whether apoptosis is triggered by DNA double strand breaks (DSBs), flow 
cytometric analyses of control, cisplatin-, 3b- and 3f-treated HCT-116 and MCF-7 populations 
were performed following co-incubation with PI (propidium iodide) and a 1o Ab (primary 
antibody) recognising -H2AX;[5] -H2AX foci appear at sites of DNA DSBs.[25] It is known that 
cisplatin causes DNA damage: inter/intrastrand DNA crosslinks, and DNA monoadducts that 
lead to DNA DSBs. These harbingers of apoptosis are largely responsible for Pt-drug antitumor 
activity.[1,23] Thus, co-incubation of cell populations with PI and 1o Ab recognising -H2AX, prior 
to flow cytometry analyses, allows cell-cycle-specific detection of sites of DNA DSBs. 
Consistent with cell cycle analyses, dual PI/-H2AX labelling of HCT-116 cells supported 3b-
induced G2/M cell cycle arrest. Interestingly, HCT-116 G2/M events comprised a population 
heavily positively stained -H2AX+ve (53 %) suggestive of the presence of DNA DSBs. Complex 
3f, in contrast (consistent with HCT-116 cell cycle analysis and reduced potency) revealed 
neither G2/M arrest, nor -H2AX-+ve events associated with this cell phase. Rather a minority 
proportion of G1 events appeared to have incurred DNA DSB damage and were -H2AX+ve. 
Validating these analyses, accumulation of G2/M cell cycle events following exposure of HCT-
116 cells to cisplatin (10 µM; 72 h was observed accompanied by -H2AX +ve events at sites of 
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DNA DSBs (Figure S11, Support Information). Obvious -H2AX +ve events were detected in G1 
and G2 cell cycle phases following exposure of MCF-7 cells to cisplatin, 3b or 3f (Supporting 
Information, Figure S12). Interestingly, chiral cyclopentadienyl complexes did not halt the cell 
cycle in treated cells and DNA DSBs (-H2AX foci) were similarly not detected.[26] Instead, 
antitumor activity of this compound was a consequence of paraptotic cell death, involving 
MAP kinase signal transduction. In contrast, current Ti complexes 3b and 3f clearly evoke 
apoptosis. 
 
Caspase activation  
Taken together, our data suggest that potent Ti-complex 3b causes later-onset apoptosis 
compared to cisplatin. To irrefutably confirm an apoptotic cell fate for cells exposed to 3b, a 
caspase 3/7 activation assay was performed following exposure of HCT-116 and MCF-7 cells 
to escalating concentrations of 3b. Dose-dependent significant caspase activation (≥5 µM 3b 
p< 0.0001; Figure 6) was detected following 72 h exposure of cells to 3b consistent with 
apoptosis-induction. As a positive control, 50 µM cisplatin was to confirm the assay raised 
caspase activation (e.g. by ~350% in HCT-116 populations; not shown). These data confirm 
that after 72 h exposure, 3b triggers apoptotic cell death (Figure 6).[27]  
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Figure 6. Dose-dependent elevation of caspase 3/7 activity in HCT-116 and MCF-7 cells 
following 72 h exposure of cells to Ti-complex 3b. Data points are mean ±S.D; (p < 0.0001, n = 
8). 
 
Conclusion 
 
A series of Ti(IV) complexes (3) has been synthesised and their structures confirmed by X-ray 
crystallography. Complex 3b evoked potent cancer-selective growth inhibitory and cytotoxic 
activity. Cell cycle analyses indicated late-onset G2/M cell cycle arrest, which at 10 µM 
(representing ~3 x GI50) triggered an apoptotic cell fate. Experiments are underway to 
determine modes of cell death and molecular targets of this promising class of titanium 
anticancer agents.   
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